A device for delivering medication directly to the eye
Official title: Lens Capsule Based Extended Drug Delivery Device
Funded at Stanford University · NIH-11033844 · Data updated 2026-11-12
This study is testing a new device that delivers medicine directly to the eye to help people with noninfectious uveitis, aiming to make treatment safer and easier by reducing the need for medications that can cause unwanted side effects.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $257,785 |
| NIH project number | 1K08EY036955-01 |
| Project ID | NIH-11033844 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with noninfectious uveitis who require ongoing treatment for ocular inflammation.
✕Less likely to help
Patients with infectious uveitis or those who do not require long-term treatment for ocular inflammation may not benefit from this research.
What this research studies
This research focuses on developing a new device that can deliver medication directly to the eye to treat noninfectious uveitis, a condition that causes inflammation. The approach involves creating a refillable lens capsule that can release biologics and immune-modulating peptides over an extended period, reducing the need for systemic medications that often have severe side effects. By using this innovative delivery method, the research aims to provide a safer and more effective treatment option for patients suffering from ocular inflammation.
Why it matters
Potential benefit: If successful, this research could provide patients with a safer, long-term treatment option for noninfectious uveitis that minimizes side effects compared to current therapies.
How similar studies have gone: Previous research has shown promise in localized drug delivery systems for ocular conditions, suggesting that this approach could be effective.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Deboer, Charles Meno Theodore — Stanford University
- Study coordinator: Deboer, Charles Meno Theodore
Related research
Other NIH-funded projects on the same topics.
-
Multimodal AI to predict CAR-T patient response and guide safer, smarter cell design
A Stanford team is building AI tools that use patient and CAR-T cell data to predict how well a CAR-T therapy will work and what design changes might boost effectiveness and safety for people with cancer.
-
Community-driven model to reduce overdose deaths through smarter resource use
A Stanford-led project uses a data-driven model to help counties pick the best ways to prevent opioid and stimulant overdoses and save lives.
-
Center for Dissemination and Implementation at Stanford: Research Core
A Stanford-based program is advancing how evidence-based addiction treatments are implemented across settings to help people with substance use disorders receive better care.
-
Center for Dissemination and Implementation At Stanford (C-DIAS)
A center-based program at Stanford aims to speed people who need addiction treatments to get evidence-based care.
-
Mitochondrial structure and neuron health in Alzheimer's and ALS
This grant studies how mitochondrial cristae structure in neurons is controlled and how its disruption may contribute to diseases like Alzheimer's and ALS.
-
Pediatric EMS seizures: simpler age-based midazolam dosing
A nationwide trial at EMS agencies tests whether using fixed, age-based dosing of midazolam for seizures in children improves treatment speed and safety.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.